Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Kodiak Sciences Inc.    KOD

KODIAK SCIENCES INC.

(KOD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/30/2020 12/01/2020 12/02/2020 12/03/2020 12/04/2020 Date
136.67(c) 130.17(c) 130.73(c) 127.05(c) 124.37(c) Last
528 601 525 054 218 598 277 820 210 353 Volume
+1.24% -4.76% +0.43% -2.81% -2.11% Change
More quotes
Financials (USD)
Sales 2020 20,8 M - -
Net income 2020 -126 M - -
Net cash position 2020 320 M - -
P/E ratio 2020 -44,6x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -215 M - -
Net cash position 2021 477 M - -
P/E ratio 2021 -27,2x
Yield 2021 -
Capitalization 6 264 M 6 264 M -
EV / Sales 2020 285x
EV / Sales 2021 -
Nbr of Employees 62
Free-Float 83,5%
More Financials
Company
Kodiak Sciences Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics to treat ophthalmic diseases. The Company’s Antibody Biopolymer Conjugate (ABC) platform focuses on merging the fields of antibody-based and chemistry-based therapies. The Company in addition to its lead product candidate, KSI-301, is a molecule for age-related macular degeneration and diabetic... 
More about the company
Notations Surperformance© of Kodiak Sciences Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about KODIAK SCIENCES INC.
11/20KODIAK SCIENCES : Announces Closing of $645.0 Million Public Offering of Common ..
PR
11/18KODIAK SCIENCES INC. : Other Events, Financial Statements and Exhibits (form 8-K..
AQ
11/17KODIAK SCIENCES : Announces Pricing of $560.9 Million Public Offering of Common ..
PR
11/16KODIAK SCIENCES : Announces Proposed Offering of Common Stock
PR
11/12KODIAK SCIENCES : to Present at Upcoming Conferences
PR
11/09KODIAK SCIENCES : Management's Discussion and Analysis of Financial Condition an..
AQ
11/09KODIAK SCIENCES INC. : Results of Operations and Financial Condition, Financial ..
AQ
10/05KODIAK SCIENCES : Treats First Patients in Three Phase 3 Studies of KSI-301 - Tw..
PR
09/02KODIAK SCIENCES : to Present at Upcoming Conferences
PR
08/20KODIAK SCIENCES INC. : Creation of a Direct Financial Obligation or an Obligatio..
AQ
08/10KODIAK SCIENCES : Management's Discussion and Analysis of Financial Condition an..
AQ
08/10KODIAK SCIENCES INC. : Results of Operations and Financial Condition, Financial ..
AQ
07/28KODIAK SCIENCES : Lonza's Ibex Dedicate to Support the Commercial Manufacture of..
AQ
07/16KODIAK SCIENCES : to Host R&D Webcast to Review Recent Data from the Ongoing Pha..
PR
06/25KODIAK SCIENCES INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
More news
News in other languages on KODIAK SCIENCES INC.
07/28Lonza va soutenir Kodiak dans la production d'un médicament ophtalmique
07/28Lonza baut Biokonjugationsanlage für Kodiak Sciences
More news
Chart KODIAK SCIENCES INC.
Duration : Period :
Kodiak Sciences Inc. Technical Analysis Chart | KOD | US50015M1099 | MarketScreener
Technical analysis trends KODIAK SCIENCES INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 114,25 $
Last Close Price 124,37 $
Spread / Highest target 16,6%
Spread / Average Target -8,14%
Spread / Lowest Target -58,2%
EPS Revisions
Managers
NameTitle
Victor Perlroth Chairman & Chief Executive Officer
John Borgeson CFO, Principal Accounting Officer & Senior VP
Jason S. Ehrlich Chief Medical & Development Officer
Sinette Heys Vice President-Clinical Operations
Felix James Baker Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
KODIAK SCIENCES INC.72.86%6 264
GILEAD SCIENCES, INC.-5.26%77 167
VERTEX PHARMACEUTICALS4.28%59 372
REGENERON PHARMACEUTICALS31.15%51 975
WUXI APPTEC CO., LTD.68.65%41 218
BIONTECH SE254.19%28 894